M
Michael E. Nassif
Researcher at Washington University in St. Louis
Publications - 66
Citations - 1310
Michael E. Nassif is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 17, co-authored 47 publications receiving 766 citations. Previous affiliations of Michael E. Nassif include University of Colorado Denver.
Papers
More filters
Journal ArticleDOI
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
Mikhail Kosiborod,Mikhail Kosiborod,Russell Esterline,Remo H.M. Furtado,Jan Oscarsson,Samvel B. Gasparyan,Gary G. Koch,Felipe Martinez,Omar Mukhtar,Subodh Verma,Subodh Verma,Vijay K. Chopra,Joan Buenconsejo,Anna Maria Langkilde,Philip Ambery,Fengming Tang,Kensey Gosch,Sheryl L. Windsor,Emily E Akin,Ronaldo V P Soares,Diogo D.F. Moia,Matthew Aboudara,Conrado R. Hoffmann Filho,Audes D. M. Feitosa,Alberto Fonseca,Vishnu Garla,Robert Gordon,Ali Javaheri,Cristiano P Jaeger,Paulo Leães,Michael E. Nassif,Michael Pursley,Fabio Serra Silveira,Weimar Kunz Sebba Barroso,José Roberto Lazcano Soto,Lilia Nigro Maia,Otavio Berwanger +36 more
TL;DR: The DARE-19 trial as discussed by the authors was a randomized, double-blind, placebo-controlled trial of patients hospitalised with COVID-19 and with at least one cardiometabolic risk factor (i.e., hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease).
Journal ArticleDOI
Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices
Michael E. Nassif,Shane J. LaRue,David S. Raymer,Eric Novak,Justin M. Vader,Gregory A. Ewald,Brian F. Gage +6 more
TL;DR: Thrombotic and bleeding outcomes in patients with continuous-flow left ventricular assist devices (CF-LVADs) are evaluated and target international normalized ratio (INR) values <2.0 increase the rate of thrombosis events occurring outside of the hospital among patients supported with CF- LVADs.
Journal ArticleDOI
Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke
Michael E. Nassif,Anjan Tibrewala,David S. Raymer,Adam Andruska,Eric Novak,Justin M. Vader,Akinobu Itoh,Scott C. Silvestry,Gregory A. Ewald,Shane J. LaRue +9 more
TL;DR: In this large, CF-LVAD cohort, elevated SBP was independently associated with a greater risk of subsequent stroke, and management of hypertension is identified as a potential modifiable risk factor for reducing the incidence of stroke in patients supported by CF- LVAD.
Journal ArticleDOI
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
John A. Spertus,Mary C. Birmingham,Michael E. Nassif,C.V. Damaraju,Antonio L'Abbate,Javed Butler,David E. Lanfear,Ildiko Lingvay,Mikhail Kosiborod,James L. Januzzi +9 more
TL;DR: The CHIEF-HF trial as discussed by the authors showed that canagliflozin significantly improves symptom burden in patients with heart failure and reduced ejection fraction (HFrEF), regardless of EF or diabetes status.
Journal ArticleDOI
Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure.
Yevgeniy Khariton,Michael E. Nassif,Laine Thomas,Gregg C. Fonarow,Xiaojuan Mi,Adam D. DeVore,Carol I. Duffy,Puza P. Sharma,Nancy M. Albert,J. Herbert Patterson,Javed Butler,Adrian F. Hernandez,Fredonia B. Williams,Kevin McCague,John A. Spertus +14 more
TL;DR: Among outpatients with HFrEF, women, blacks, Hispanics, and poorer patients had worse health status, which remained significant for women, Hispanics and richer patients in fully adjusted analyses, and suggests an opportunity to further optimize treatment to reduce these observed disparities.